Streebo offers a free look at Sunshine Act data compiled by type, company and physician
    It hasn't taken long for IT companies serving the pharma industry to make use of the publicly available data on aggregate spending on physicians, an outcome of the Physicians Sunshine Act. One of the first out the gate is Streebo (Houston), a boutique business-analytics and software developer that counts a number of pharma companies (Eisai, Otsuka, Sunovion) among its customer base. Streebo has launched, and is offering free access to qualified pharma employees to peruse the data published on the latter half of 2013 in the CMS Open Payments database, which initially became available last September. Mohammed Ovais, managing partner, says that the 2014
    Mevion's compact S250 unit bids to change the economics of radiation oncology
    In some circles, proton beam accelerators (PBAs) are looked on as a bad case of overreach by hospital systems scrambling to offer the latest and greatest in cancer care with little regard for health economics or outcomes. Until recently, the devices were massive units costing hundreds of millions of dollars; there are about 25 units in operation or various stages of commissioning across the country, and already there are questions whether the units are cannibalizing each other's base of potential patients
    AstraZeneca's Seroquel XR sample kit takes top honors
    An annual tradition since 1995, the Healthcare Compliance Packaging Council's Package of the year winner, this year, is a blister-carded 14-day sample kit from AstraZeneca, for its Seroquel XR (extended release quetiapine), an "atypical antipsychotic" for treatment of a variety of mental health conditions. First Runner-Up is Eli Lilly's Strattera (atomoxetine, for ADHD) physician's sample pack, and Second Runner-Up is the Exforge HCT blister package. Novartis' Exforge HCT (amlodipine, valstartan, hydrochlorothiazide) is indicated for high blood-pressure treatment and is taken
    Besides specialty pharmaceutical pricing, the cost of compounded drugs is highlighted
    For the past two years, Express Scripts has gone well beyond its traditional role in winning rebates from pharma manufacturers and actively managing drug regimens for the patients whose drug-benefit plans it oversees: In 2013 it announced that 48 branded drugs would be on a "formulary exclusion list" for cases where a roughly equivalent generic or lower-cost branded drug was available. Over much of last year it agitated very publicly for a lower cost for Gilead Sciences' hepatitis C cure, Sovaldi (sofosbuvir), and at the end of the year said it would provide for the newly approved competitor
    'Filgrastim-sndz' is Sandoz' Zarxio, the biosimilar of Amgen's Neuprogen
    Following a unanimous approval by a review panel in January, FDA has approved the commercial distribution of the biosimilar form of filgrastim, aka Amgen's Neuprogen. Sandoz' press release, issued on the same day as FDA's, doesn't say anything about a distribution timetable, and a Reuters report says that Amgen is suing to block the sale in the US; a decision on a preliminary injunction is expected in the next couple weeks. That article also puts global filgrastim sales at around $1.2 billion worldwide; Sandoz has been marketing its biosimilar for several years already, as Zarzio. In the US, if the Amgen suit is resolved favorably for Sandoz,
Pharmaceutical Commerce
Digital Edition
Current Digital Edition
Read the May/June 2015 Issue now - It's Free!
Pharmaceutical Commerce’s annual Cold Chain Sourcebook projects 44% growth over the 2013–2019 span
Pharmaceutical Commerce sat down with Dahod to talk about DSCSA, the pharma industry's current supply chain management capabilities, and the future outlook of commercial IT management. Here's what he had to say.
Combining high-quality patient-support services with comprehensive and continually updated analytics results in better outcomes  continued >
The growing number of certifications has become a competitive issue for SPPs bidding for Pharma's business  continued >
As new cancer drugs with promising efficacy but brutal costs enter the market, providers, payers and manufacturers are strategizing new payment approaches  continued >
Heightened concern over adherence and product stability may win over more pharma clients  continued >
2015 Product Security Report
Meeting the compliance deadlines of the Drug Supply Chain Security Act has the attention of many in biopharma product and brand security
Use of state-of-the-art software, combined with benchmarking and active oversight, fills this gap 
  |     |     |     |     |     |  
©2015 Pharmaceutical Commerce. All Rights Reserved.  |  Website managed and designed by Offenberger & White.